AVTX [NASD]
Avalo Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.71 Insider Own0.20% Shs Outstand112.79M Perf Week30.01%
Market Cap40.29M Forward P/E- EPS next Y-0.49 Insider Trans- Shs Float111.98M Perf Month-43.01%
Income-75.80M PEG- EPS next Q-0.15 Inst Own73.20% Short Float1.86% Perf Quarter-60.65%
Sales6.10M P/S6.60 EPS this Y12.50% Inst Trans2.27% Short Ratio4.63 Perf Half Y-84.89%
Book/sh0.06 P/B5.42 EPS next Y18.10% ROA-100.50% Target Price3.55 Perf Year-87.65%
Cash/sh0.31 P/C1.05 EPS next 5Y- ROE-331.80% 52W Range0.20 - 3.70 Perf YTD-80.89%
Dividend- P/FCF- EPS past 5Y14.70% ROI-146.60% 52W High-91.22% Beta2.20
Dividend %- Quick Ratio2.40 Sales past 5Y36.20% Gross Margin65.00% 52W Low60.92% ATR0.06
Employees42 Current Ratio2.40 Sales Q/Q140.00% Oper. Margin- RSI (14)36.86 Volatility15.81% 17.26%
OptionableYes Debt/Eq5.27 EPS Q/Q43.40% Profit Margin- Rel Volume1.07 Prev Close0.32
ShortableYes LT Debt/Eq5.27 Earnings- Payout- Avg Volume449.14K Price0.32
Recom1.60 SMA20-12.64% SMA50-41.53% SMA200-79.28% Volume482,611 Change1.53%
Sep-24-21Initiated RBC Capital Mkts Outperform $6
May-18-22 07:30AM  
May-17-22 07:30AM  
May-05-22 07:30AM  
Mar-08-22 07:00AM  
Mar-02-22 07:30AM  
Feb-17-22 07:30AM  
Feb-07-22 04:01PM  
Jan-10-22 07:59PM  
Jan-06-22 07:30AM  
Dec-16-21 07:30AM  
Dec-06-21 07:30AM  
Dec-05-21 06:43AM  
Nov-11-21 07:00AM  
Nov-09-21 04:01PM  
Oct-13-21 07:00AM  
Oct-06-21 04:15PM  
Sep-20-21 07:00AM  
Sep-17-21 09:11AM  
Sep-14-21 10:23PM  
04:01PM  
Sep-06-21 06:43AM  
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. Its product pipeline includes AVTX-002, an Anti-LIGHT mAb targeting immune-inflammatory diseases, including acute respiratory distress syndrome and moderate-to-severe inflammatory bowel disease; and AVTX-007, an Anti-IL-18 mAb targeting immuno-oncology and immune-inflammatory diseases, including multiple myeloma and Still's disease. The company also engages in developing AVTX-006, a dual mTORc1/c2 inhibitor targeting lymphatic malformations; and AVTX 800 programs (AVTX-801, AVTX-802, and AVTX-803), which are therapeutic doses of monosaccharide therapies for congenital disorders of glycosylation. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ARMISTICE CAPITAL, LLCDirectorMar 14Buy0.65100,00064,94047,576,000Mar 14 05:38 PM
ARMISTICE CAPITAL, LLCDirectorMar 11Buy0.69100,00068,78047,476,000Mar 14 05:38 PM
ARMISTICE CAPITAL, LLCDirectorMar 10Buy0.7026,00018,22647,376,000Mar 14 05:38 PM
ARMISTICE CAPITAL, LLCDirectorMar 07Buy0.66325,000213,33047,350,000Mar 07 06:09 PM
ARMISTICE CAPITAL, LLCDirectorMar 04Buy0.70135,00095,10847,025,000Mar 07 06:09 PM
ARMISTICE CAPITAL, LLCDirectorMar 03Buy0.7150,00035,69546,890,000Mar 07 06:09 PM
ARMISTICE CAPITAL, LLCDirectorFeb 25Buy0.7940,00031,71646,840,000Feb 28 05:53 PM
ARMISTICE CAPITAL, LLCDirectorFeb 24Buy0.80100,00080,09046,800,000Feb 28 05:53 PM
ARMISTICE CAPITAL, LLCDirectorFeb 22Buy0.7783,00064,07646,700,000Feb 22 06:37 PM
ARMISTICE CAPITAL, LLCDirectorFeb 18Buy0.8255,00045,23846,617,000Feb 22 06:37 PM
ARMISTICE CAPITAL, LLCDirectorFeb 17Buy0.81150,000122,25046,562,000Feb 22 06:37 PM
ARMISTICE CAPITAL, LLCDirectorJan 20Buy0.8512,00010,20846,412,000Jan 20 06:14 PM
ARMISTICE CAPITAL, LLCDirectorJan 19Buy0.8893,70082,05346,400,000Jan 20 06:14 PM
ARMISTICE CAPITAL, LLCDirectorJan 18Buy0.88206,300182,22546,306,300Jan 20 06:14 PM
ARMISTICE CAPITAL, LLCDirectorJan 14Buy0.9385,00078,97446,100,000Jan 14 05:49 PM
ARMISTICE CAPITAL, LLCDirectorJan 13Buy1.00312,700314,01346,015,000Jan 14 05:49 PM
ARMISTICE CAPITAL, LLCDirectorJan 12Buy1.0457,30059,78145,702,300Jan 14 05:49 PM
ARMISTICE CAPITAL, LLCDirectorJan 11Buy0.9616,00315,34245,645,000Jan 11 06:18 PM
ARMISTICE CAPITAL, LLCDirectorJan 10Buy0.99491,097484,61545,628,997Jan 11 06:18 PM
ARMISTICE CAPITAL, LLCDirectorJan 07Buy1.04137,900142,97545,137,900Jan 11 06:18 PM
Wilkins H JeffreyChief Medical OfficerDec 10Buy1.576,37110,00233,373Dec 14 06:19 PM
Harrell James Archie JrChief Commercial OfficerDec 10Buy1.571,0931,71636,766Dec 14 05:16 PM
Sullivan Christopher RyanChief Accounting OfficerDec 10Buy1.579551,4999,004Dec 14 05:17 PM
NEIL GARRY ARTHURChief Scientific OfficerDec 10Buy1.574,2676,69985,639Dec 14 05:15 PM
Greenway Schond L.CFODec 10Buy1.572,2313,5033,883Dec 14 05:13 PM